NCT03282825 - Clinical Study of Decitabine and Paclitaxel Combination Therapy | Biotech Hunter

Enrollment

18

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

May 31, 2018

Conditions

Advanced Breast Cancer

Interventions

DRUG

Decitabine

"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."

DRUG

Paclitaxel

"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."

Trial Locations (1)

03722

Yonsei University Health System, Severance Hospital, Seoul